Practice

Researchers Find Low Infection Risk With Denosumab Plus Other Biologics

November 29th 2017

By Samantha DiGrande

A recent study was conducted to determine whether the concurrent use of denosumab with a biologic disease-modifying antirheumatic drug (bDMARD), such as adalimuab, etanercept, or infliximab, increases the risk of infection.

Biologics, and Costs, Are on the Rise in IBD Treatment, Study Finds

November 28th 2017

By The Center for Biosimilars Staff

Article

Biologics are increasingly used in the treatment of inflammatory bowel disease (IBD), but real-world data quantifying the costs of these therapies have been lacking. A new study, published in Alimentary Pharmacology and Therapeutics, sought to determine trends in costs and relative market share of IBD therapies in the United States over the past 9 years.

Humira Competitor Tremfya Gains European Approval for Psoriasis Treatment

November 28th 2017

By Jackie Syrop

Article

Janssen-Cilag International’s biologic drug guselkumab (Tremfya) has received approval from the European Commission (EC) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Will Biosimilar Trastuzumab Change Clinical Practice?

November 27th 2017

By Samantha DiGrande

Article

Trastuzumab has been used to manage both early and metastatic HER2-postive breast cancer and has significantly improved the survival of these patients and become the standard of care, according to Arlene Chan, MB BS, FRACP, MMed, writing in Chinese Clinical Oncology.

Switching to CT-P13 Associated With Loss of Response in Patients With Behçet's Disease

November 22nd 2017

By Kelly Davio

Article

A recent case report, published in the European Journal of Rheumatology, showed that switching to biosimilar infliximab resulted in a rapid loss of efficacy in 3 patients with Behçet’s disease (BD), a chronic, relapsing, systemic vasculitis.

Amgen Launches Auto-Injector for Reference Etanercept

November 18th 2017

By Jackie Syrop

Article

In an effort to better address the needs of patients taking reference etanercept (Enbrel), Amgen has launched an ergonomically designed cartridge with a reusable auto-injector in the United States as an additional administration option.

The Top 5 Biosimilars Articles for the Week of November 13

November 17th 2017

By The Center for Biosimilars Staff

Article

The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of November 13.

Neutrophils, G-CSF, and Breast Cancer Metastasis: A Reason for Caution?

November 17th 2017

By Jackie Syrop

Article

Australian researchers Kellie A. Mouchemore, PhD, and colleagues urge caution in the use of granulocyte colony stimulating factor (G-CSF) in neutrophil recovery following chemotherapy for breast cancer because there is increasing evidence that G-CSF can promote metastasis.

Mylan Head Warns of "Whisper Campaign" Against Biosimilars

November 16th 2017

By Kelly Davio

Article

At a Wednesday session of the SMi Biosimilars North America conference, Chrys Kokino, MBA, head of Mylan’s global biologics commercial division, said that biosimilars can be part of improving access to and affordability of biologic therapies for patients worldwide, but also highlighted the hurdles that biosimilar developers will have to overcome as they seek to gain a foothold in the US marketplace.

Biogen Partners with Theradiag on Biosimilar Infliximab Monitoring Kits

November 15th 2017

By Jackie Syrop

Article

Theradiag, a French company that specializes in in vitro diagnostics and theranostics, has entered into a partnership agreement with Biogen to provide its Lisa Tracker kits to monitor patients treated with Biogen’s infliximab biosimilar Flixabi, which was approved in Europe in 2016.